Novartis India to offer staff gender-neutral' insurance
From January 1, 2020, employees at drugmaker Novartis India will be covered by a gender-neutral insurance benefit plan that will cover LGBTI, single20-12-2019
20-12-2019
NOVARTIS INDIA LTD. - 500672 - Compliances-Reg. 39 (3) - Details of Loss of Certificate / Duplicate Certificate
Dear Sirs, Please note that in terms of the applicable provisions of the SEBI Listing Regulations, the Company has received intimation regarding loss of share certificate from the following shareholder: Stop Transfer Date - December 16, 2019 Folio No. 03092563 Name of the shareholder -Rahul Ruplal Ganvir Certificate No. 20361 Distinctive No. 15754088 - 15754097 No. of shares - 10 Reason - Lost by holder The Registrar and Share Transfer Agent of the Company i.e. Link lntime India Private Limited has received a request letter from the abovementioned shareholder and have informed the Company about the same today i.e. on December 17, 2019. Further, subject to completion of required formalities by the shareholder, the Company will issue duplicate share certificate in lieu thereof. Thanking you17-12-2019
Novartis sees larger India role in its drug development value chain
Arno Tellmann, Head Global Drug Development India, said that the GDD in Hyderabad over the years has evolved from just being a back-office support function to playing a much bigger role in drug development work of Novartis.12-12-2019
Anti-diabetes drug Vildgliptin to become 80% cheaper
The patents for Vildagliptin in India held by Novartis were expired on December 9, opening the market for cheap rip-offs.10-12-2019
Eris buys trademark for Novartis drug for $13 million
Zomelis is used to treat type-2 diabetes04-12-2019
NOVARTIS INDIA LTD. - 500672 - Disclosure Of Related Party Transactions For The Half Year Ended On September 30, 2019
Apropos the subject matter quoted above, please find enclosed herewith the disclosure of Related Party Transactions on a standalone basis, in format as specified in the relevant accounting standards for the half year ended on September 30, 2019. The above is for your information and the same is also available on the Company''s website i.e. www.novartis.in Thanking you.04-12-2019
NOVARTIS INDIA LTD. - 500672 - Compliances-Reg. 39 (3) - Details of Loss of Certificate / Duplicate Certificate
Dear Sirs, Please note that in terms of the applicable provisions of the SEBI Listing Regulations, the Company has received intimation regarding loss of share certificate from the following shareholder: Stop Transfer date - December 2, 2019 Folio No. 01074024 Name - K. Shakuntala Karanth Certificate No- 3473 Distinctive No. 338357 - 338422 No. of shares - 66 Reason - Lost by holder The Registrar and Share Transfer Agent of the Company i.e. Link lntime India Private Limited has received a request letter from the abovementioned shareholder and have informed the Company about the same today i.e. on December 3, 2019. Further, subject to completion of required formalities by the shareholder, the Company will issue duplicate share certificate in lieu thereof. Thanking you04-12-2019
Novartis India Ltd - 500672 - Announcement under Regulation 30 (LODR)-Code of Conduct under SEBI (PIT) Regulations, 2015
Dear Sirs, Pursuant to the Securities and Exchange Board of India (Prohibition of Insider Trading) (Third Amendment) Regulations, 2019, we would like to inform you that the Board of Directors of the Company have approved the amendments to its existing Code. Please find enclosed a copy of the revised Code of the Company. The same is also available on the website of the Company www.novatis.in. Thanking you.29-11-2019
Novartis takes on Sanofi, Amgen with $9.7-bn takeover of heart drug maker
Novartis shares were seen up 0.2%, premarket indicators showed.26-11-2019
Novartis Sickle-Cell Drug Gets US Approval
The drug will be priced between $84,852 and $113,136 per year for most patients, who will typically infuse themselves with between three and four vials each month, Novartis said.16-11-2019